Total
0
Shares
Source: Nutritional High.
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • High Fusion (FUZN) subsidiary, Neural Therapeutics has announced plans to complete a non-brokered private placement of units for proceeds of up to $750,000
  • Units will be comprised of one common share of Neural Therapeutics and one-half of one common share purchase warrant
  • Net proceeds from the offering will be used for research and development and general working capital
  • High Fusion is focused on developing and manufacturing branded products in the cannabis industry
  • Neural Therapeutics, a wholly-owned subsidiary of High Fusion, is an ethnobotanical drug discovery and development company
  • High Fusion Inc. (FUZN) opened trading at C$0.16 per share

High Fusion (FUZN) subsidiary, Neural Therapeutics has announced a non-brokered private placement of units for proceeds of up to $750,000.

Units will be comprised of one common share of Neural Therapeutics and one-half of one common share purchase warrant. Each whole warrant will be exercisable into one Neural Share at an exercise price of $0.10.

Net proceeds from the offering will be used for research and development and general working capital. 

High Fusion is focused on developing and manufacturing branded products in the cannabis industry with a specific focus on flower, pro-rolls, vapes, edibles and oil extracts for medical and adult recreational use. The company operates in California, Colorado and Oregon.

High Fusion has manufacturing, retail and grow operations in California through its acquisition of OutCo and operates oil extraction and edible manufacturing facilities in Colorado and Oregon. 

Neural Therapeutics, a wholly-owned subsidiary of High Fusion, is an ethnobotanical drug discovery and development company.

High Fusion Inc. (FUZN) opened trading at C$0.16 per share.

More From The Market Herald
Eve and Co - CEO, Melinda Rombouts

" Eve & Co (TSXV:EVE) releases 2021 year-to-date financial results

Eve & Co (EVE) reported gross revenues of $6.5 million in the first nine months of 2021.

" Elixxer Ltd. (TSXV:ELXR) welcomes new director

Elixxer (ELXR) is pleased to welcome Mr. Jeremy Green to the corporation’s board of directors. 
White Gold Corp - David D'Onofrio, CEO

" White Gold Corp. (TSXV:WGO) announces fully subscribed private placement

White Gold (WGO) has announced a non-brokered private placement for total gross proceeds of approximately $9,000,000.

" Hemlo Explorers (TSXV:HMLO) closes first tranche of private placement

Hemlo Explorers (HMLO) has closed the first tranche of its non-brokered private placement for gross proceeds of approximately $1.5 million.